Efficacy of Zhuling polyporus polysaccharide with BCG to inhibit bladder carcinoma

被引：28

作者：

Zhang, Guo-wei ^{[1
]}

Qin, Gui-fang ^{[1
]}

Han, Bo ^{[1
]}

Li, Cai-xia ^{[2
]}

Yang, Hong-Gai ^{[1
]}

Nie, Pi-hu ^{[1
]}

Zeng, Xing ^{[3
]}

机构：

[1] Hebei Univ, Coll Chinese Med, Baoding 071002, Peoples R China

[2] Guangzhou Univ Chinese Med, Sch Basic Med Sci, Guangzhou 510006, Guangdong, Peoples R China

[3] Guangdong Prov Tradit Chinese Med Hosp, Guangdong Prov Acad Chinese Med Sci, Guangzhou 510006, Guangdong, Peoples R China

来源：

CARBOHYDRATE POLYMERS | 2015年 / 118卷

关键词：

Bacille Calmette-Guerin; Sclerotia of Polyporus umbellatus FRIES; Polyporus polysaccharide; Bladder carcinoma; IMMUNE-RESPONSE; CELL; CANCER; CARCINOGENESIS; IMMUNOTHERAPY; ACTIVATION; THERAPY; LIGAND;

D O I：

10.1016/j.carbpol.2014.11.012

中图分类号：

O69 [应用化学];

学科分类号：

081704 ;

摘要：

There is growing interest in reducing Bacille Calmette-Guerin (BCG) side effects while keeping intact its therapeutic efficacy. In the present study, we evaluated the efficacy of Sclerotia of Polyporus umbellatus FRIES (Zhuling) and its main ingredient Polyporus Polysaccharide (PPS) to attenuate side effects of BCG therapy in vivo. The results show that bladder cancer development in model rats exhibited significantly reduced cancer invasiveness with Zhuling PPS combined with BCG. Flow cytometric (FCM) analysis showed expression of costimulatory molecules CD86, CD40, and TLR4/CD14 significantly increased with Zhuling PPS in combination with BCG. Similarly, immunohistochemical analysis revealed stronger CD86 and CD40 staining. Our findings show Zhuling PPS strongly reduced side effects and displayed synergistic effects during BCG instillation in rat bladder cancer models. The findings also suggest that the attenuation effect may result from direct activation of dendritic cell (DC) TLR4. (C) 2014 Elsevier Ltd. All rights reserved.

引用

页码：30 / 35

页数：6

共 24 条

[1] Serum Th1 and Th2 cytokine balance in patients of superficial transitional cell carcinoma of bladder pre- and post-intravesical combination immunotherapy [J].

Agarwal, Abhilasha ;

Agrawal, Usha ;

Verma, Saurabh ;

Mohanty, Nayan Kumar ;

Saxena, Sunita .

IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY, 2010, 32 (02) :348-356

[2] Role for CD40-CD40 ligand interactions in the immune response to solid tumours [J].

Alexandroff, AB ;

Jackson, AM ;

Paterson, T ;

Haley, JL ;

Ross, JA ;

Longo, DL ;

Murphy, WJ ;

James, K ;

Taub, DD .

MOLECULAR IMMUNOLOGY, 2000, 37 (09) :515-526

[3] MANIPULATION OF COSTIMULATORY SIGNALS TO ENHANCE ANTITUMOR T-CELL RESPONSES [J].

ALLISON, JP ;

HURWITZ, AA ;

LEACH, DR .

CURRENT OPINION IN IMMUNOLOGY, 1995, 7 (05) :682-686

[4] Immune and clinical outcomes in patients with stage IV melanoma vaccinated with peptide-pulsed dendritic cells derived from CD34+ progenitors and activated with type I interferon [J].

Banchereau, J ;

Ueno, H ;

Dhodapkar, M ;

Connolly, J ;

Finholt, JP ;

Klechevsky, E ;

Blanck, JP ;

Johnston, DA ;

Palucka, AK ;

Fay, J .

JOURNAL OF IMMUNOTHERAPY, 2005, 28 (05) :505-516

[5]

Chang HM., 1986, PHARM APPL CHINESE M, VI

[6] Differential regulation of cell survival by CD40 [J].

Dallman, C ;

Johnson, PWM ;

Packham, G .

APOPTOSIS, 2003, 8 (01) :45-53

[7] Alterations of Dendritic Cell Subsets and Th1/Th2 Cytokines in the Peripheral Circulation of Patients With Superficial Transitional Cell Carcinoma of the Bladder [J].

Feng Lang ;

Ma Linlin ;

Tian Ye ;

Zhang Yuhai .

JOURNAL OF CLINICAL LABORATORY ANALYSIS, 2012, 26 (05) :365-371

[8] Impact of surgery and epirubicin intravesical chemotherapy on peripheral blood dendritic cell subsets in patients with superficial urothelial carcinoma of the bladder [J].

Feng Lang ;

Ma Lin-lin ;

Zhang Yu-hai ;

Tian Ye ;

Qu Chen-xue ;

Wang Yang .

CHINESE MEDICAL JOURNAL, 2012, 125 (07) :1254-1260

[9] Requirement for CD40 ligand in costimulation induction, T cell activation, and experimental allergic encephalomyelitis [J].

Grewal, IS ;

Foellmer, HG ;

Grewal, KD ;

Xu, JC ;

Hardardottir, F ;

Baron, JL ;

Janeway, CA ;

Flavell, RA .

SCIENCE, 1996, 273 (5283) :1864-1867

[10] Immunotherapy - Fusion induces tumour rejection [J].

Hart, I ;

Colaco, C .

NATURE, 1997, 388 (6643) :626-627

← 1 2 3 →